Aquestive Therapeutics resubmits NDA for Anaphylm
The company said it resubmitted its New Drug Application for Anaphylm after supportive human factors and pharmacokinetic study results.
Key Highlights:Original SEC Filing: Aquestive Therapeutics, Inc. [ AQST ] - 8-K - Sep. 17, 2026This is an AI-powered summary. It may contain inaccuracies.
Co…